Summit Therapeutics to Participate in JMP Securities Life Sciences Conference
June 15 2017 - 7:00AM
Summit Therapeutics plc (“Summit”, or the “Company”)
(NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development
company advancing therapies for Duchenne muscular dystrophy (‘DMD’)
and Clostridium difficile infection, announces that Glyn Edwards,
CEO of Summit, will participate in a DMD pipeline panel discussion
at the JMP Securities Life Sciences Conference on 21 June 2017 at
8:30am EDT in New York City.
In addition, Summit will hold one-on-one
meetings at the conference. There will be no webcast of the
panel.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease, Duchenne muscular dystrophy, and the infectious
disease, Clostridium difficile infection. Further information is
available at www.summitplc.com and Summit can be followed on
Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics Glyn Edwards
/ Richard Pye (UK office)Erik Ostrowski / Michelle
Avery (US office) |
Tel: +44
(0)1235 443 951 +1 617 225 4455 |
|
|
Cairn Financial Advisers LLP (Nominated
Adviser)Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 7213 0880 |
|
|
N+1 Singer (Broker)Aubrey Powell / Lauren
Kettle |
Tel: +44 (0)20 7496 3000 |
|
|
MacDougall Biomedical Communications(US media
contact)Karen Sharma |
Tel: +1
781 235 3060 ksharma@macbiocom.com |
|
|
Consilium Strategic Communications (Financial
public relations, UK)Mary-Jane Elliott / Sue Stuart / Jessica
Hodgson / Lindsey Neville |
Tel: +44
(0)20 3709 5700summit@consilium-comms.com |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Apr 2023 to Apr 2024